144 related articles for article (PubMed ID: 7600561)
1. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration.
Adams GP; McCartney JE; Wolf EJ; Eisenberg J; Tai MS; Huston JS; Stafford WF; Bookman MA; Houston LL; Weiner LM
Cancer Immunol Immunother; 1995 May; 40(5):299-306. PubMed ID: 7600561
[TBL] [Abstract][Full Text] [Related]
2. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.
Adams GP; Tai MS; McCartney JE; Marks JD; Stafford WF; Houston LL; Huston JS; Weiner LM
Clin Cancer Res; 2006 Mar; 12(5):1599-605. PubMed ID: 16533787
[TBL] [Abstract][Full Text] [Related]
3. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv.
Adams GP; McCartney JE; Tai MS; Oppermann H; Huston JS; Stafford WF; Bookman MA; Fand I; Houston LL; Weiner LM
Cancer Res; 1993 Sep; 53(17):4026-34. PubMed ID: 7689421
[TBL] [Abstract][Full Text] [Related]
4. Tumor targeting in a murine tumor xenograft model with the (sFv')2 divalent form of anti-c-erbB-2 single-chain Fv.
Huston JS; Adams GP; McCartney JE; Tai MS; Hudziak RM; Oppermann H; Stafford WF; Liu S; Fand I; Apell G
Cell Biophys; 1994; 24-25():267-78. PubMed ID: 7736532
[TBL] [Abstract][Full Text] [Related]
5. Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides.
McCartney JE; Tai MS; Hudziak RM; Adams GP; Weiner LM; Jin D; Stafford WF; Liu S; Bookman MA; Laminet AA
Protein Eng; 1995 Mar; 8(3):301-14. PubMed ID: 7479692
[TBL] [Abstract][Full Text] [Related]
6. Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers.
Tai MS; McCartney JE; Adams GP; Jin D; Hudziak RM; Oppermann H; Laminet AA; Bookman MA; Wolf EJ; Liu S
Cancer Res; 1995 Dec; 55(23 Suppl):5983s-5989s. PubMed ID: 7493381
[TBL] [Abstract][Full Text] [Related]
7. Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation.
Adams GP; McCartney JE; Wolf EJ; Eisenberg J; Huston JS; Bookman MA; Moldofsky P; Stafford WF; Houston LL; Weiner LM
J Nucl Med; 1995 Dec; 36(12):2276-81. PubMed ID: 8523119
[TBL] [Abstract][Full Text] [Related]
8. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide.
George AJ; Jamar F; Tai MS; Heelan BT; Adams GP; McCartney JE; Houston LL; Weiner LM; Oppermann H; Peters AM
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8358-62. PubMed ID: 7667295
[TBL] [Abstract][Full Text] [Related]
9. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
Adams GP; Schier R; Marshall K; Wolf EJ; McCall AM; Marks JD; Weiner LM
Cancer Res; 1998 Feb; 58(3):485-90. PubMed ID: 9458094
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library.
Schier R; Marks JD; Wolf EJ; Apell G; Wong C; McCartney JE; Bookman MA; Huston JS; Houston LL; Weiner LM
Immunotechnology; 1995 May; 1(1):73-81. PubMed ID: 9373335
[TBL] [Abstract][Full Text] [Related]
11. Single-chain Fv radioimmunotargeting.
Huston JS; George AJ; Adams GP; Stafford WF; Jamar F; Tai MS; McCartney JE; Oppermann H; Heelan BT; Peters AM; Houston LL; Bookman MA; Wolf EJ; Weiner LM
Q J Nucl Med; 1996 Sep; 40(3):320-33. PubMed ID: 8961808
[TBL] [Abstract][Full Text] [Related]
12. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo.
Stackhouse MA; Buchsbaum DJ; Grizzle WE; Bright SJ; Olsen CC; Kancharla S; Mayo MS; Curiel DT
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):817-22. PubMed ID: 9845103
[TBL] [Abstract][Full Text] [Related]
14. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
15. Medical applications of single-chain antibodies.
Huston JS; McCartney J; Tai MS; Mottola-Hartshorn C; Jin D; Warren F; Keck P; Oppermann H
Int Rev Immunol; 1993; 10(2-3):195-217. PubMed ID: 8360586
[TBL] [Abstract][Full Text] [Related]
16. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
Adams GP; Schier R; McCall AM; Crawford RS; Wolf EJ; Weiner LM; Marks JD
Br J Cancer; 1998 May; 77(9):1405-12. PubMed ID: 9652755
[TBL] [Abstract][Full Text] [Related]
17. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
18. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA
Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388
[TBL] [Abstract][Full Text] [Related]
19. Improved tumor radioimmunodetection using a single-chain Fv and gamma-interferon: potential clinical applications for radioimmunoguided surgery and gamma scanning.
Nieroda CA; Milenic DE; Carrasquillo JA; Scholm J; Greiner JW
Cancer Res; 1995 Jul; 55(13):2858-65. PubMed ID: 7796413
[TBL] [Abstract][Full Text] [Related]
20. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota T; Milenic DE; Whitlow M; Schlom J
Cancer Res; 1992 Jun; 52(12):3402-8. PubMed ID: 1596900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
